Greater availability of naloxone spray, including over the counter, may reduce opioid overdoses; vaccination rates drop once again for US children; some experts question the necessity of the updated COVID-19 booster shot.
In response to increasing rates of opioid overdoses, particularly fentanyl, federal policy is shifting to make the overdose reversal drug naloxone more accessible to the public, according to CNN. More than 107,000 people died from a drug overdose in the 12-month period ending in August 2022, with fentanyl accounting for two-thirds of those deaths. Annual doses of naloxone dispensed have increased 9-fold in the past 5 years, but opportunities for improvement remain. The FDA plans to meet next month to review the first application for an OTC naloxone nasal spray, but concerns over price and resource waste pose potential issues.
Vaccination rates during the 2021-2022 school year dipped once again for US kindergarten-age children against diseases such as polio, measles, and diphtheria, according to Reuters. Overall, those receiving state-required vaccinations decreased to about 93% last year, which suggests a decline from the previous school year (94%) and the 2019-2020 school year (95%), according to the CDC. Vaccine experts believe that accessibility and poverty issues must be addressed to bring vaccination rates back to prepandemic levels.
New data suggest the new COVID-19 booster isn’t much more effective in generating neutralizing antibodies than the original vaccine, according to TIME. Further research showed that the bivalent booster did not produce significantly different antibody responses against newer Omicron variants, which accounted for 84% of new infections in the United States in the first week of January. These data lead vaccine expert Paul A. Offit, MD, director of vaccine education and attending physician in the Division of Infectious Diseases at Children’s Hospital of Philadelphia, to believe that chasing variants of COVID-19 with boosters may not produce better responses.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More